Activin and Inhibin

AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC 50 of 0.16 μM.In VivoAM-1638 exhibits moderate cross-species plasma clearance and volume of distribution, resulting in plasma half-lives suitable for evaluation of its

AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC 50 of 0.16 μM.In VivoAM-1638 exhibits moderate cross-species plasma clearance and volume of distribution, resulting in plasma half-lives suitable for evaluation of its

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC 50 of 0.16 μM for human Nav1.7.In VitroIn heterologous cells, comparable inhibition is observed across human, mouse, dog, and cynomolgus monkey NaV1.7 with

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC 50 of 0.16 μM for human Nav1.7.In VitroIn heterologous cells, comparable inhibition is observed across human, mouse, dog, and cynomolgus monkey NaV1.7 with

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC 50 of 0.16 μM for human Nav1.7.In VitroIn heterologous cells, comparable inhibition is observed across human, mouse, dog, and cynomolgus monkey NaV1.7 with

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC 50 of 0.16 μM for human Nav1.7.In VitroIn heterologous cells, comparable inhibition is observed across human, mouse, dog, and cynomolgus monkey NaV1.7 with

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC 50 of 0.16 μM for human Nav1.7.In VitroIn heterologous cells, comparable inhibition is observed across human, mouse, dog, and cynomolgus monkey NaV1.7 with

AM-5308 is a potent kinesin KIF18A inhibitor (WO2021211549A1, C13).Form:Solid.

AM-5308 is a potent kinesin KIF18A inhibitor (WO2021211549A1, C13).Form:Solid.

AM-5308 is a potent kinesin KIF18A inhibitor (WO2021211549A1, C13).Form:Solid.

AM-5308 is a potent kinesin KIF18A inhibitor (WO2021211549A1, C13).

AM6538 is a long-acting, high affinity and pseudo-irreversible cannabinoid (CB) antagonist. AM6538 is a structural analog of rimonabant. AM6538 can be effectively used to evaluate the apparent efficacy of cannabinoid full and partial agonists.